Amid escalating backlash over its involvement with England's National Health Service, Palantir Technologies has made a significant appointment to its British operations: Tom Watson, the former deputy leader of the ruling Labour party, has joined as a senior vice president. The move marks a striking reversal for Watson, who a decade earlier had pursued legal action against the UK Government over surveillance plans.
Louis Mosley, Palantir's UK chief, characterized Watson's hiring by saying he "brings deep understanding of how AI is changing the ways the state can help people in Britain." The company confirmed that Watson would step back from his seat in the House of Lords and surrender his parliamentary credentials during his tenure. Yet the appointment appears designed to serve purposes beyond Watson's stated expertise.
Watson spent more than two decades in Parliament, holding ministerial roles in defence and digital matters. His political pedigree and insider networks make him a valuable asset as Palantir confronts a critical juncture: a contractual break clause that could permit the Government to terminate its £330m partnership with the NHS's Federated Data Platform before the year ends. Ministers have remained silent on whether they intend to exercise this option.
Opposition to Palantir's continued involvement has intensified substantially. Cross-party parliamentary committees have urged the NHS to end the contract, citing concerns that span from founder Peter Thiel's public criticism of the NHS—he has described it as making "people sick"—to the company's alignment with United States President Donald Trump and its support for immigration enforcement operations, alongside worries about threats to British sovereignty.
Watson's appointment may also represent an attempt to fill a void created by the recent departure of another influential Labour peer. Peter Mandelson, whose lobbying firm Global Counsel represented Palantir as a significant client, served as British Ambassador to the United States. During his ambassadorial tenure, Mandelson retained a financial stake in Global Counsel, which continued advising Palantir—an arrangement whose governance remained opaque.
Mandelson accompanied Prime Minister Keir Starmer to Palantir's offices during Starmer's inaugural Washington visit in 2025, positioning the meeting as the second stop after the White House. Government documents reveal that Mandelson subsequently emailed Starmer's chief of staff proposing a meeting between the Prime Minister and Palantir founder Peter Thiel, referring to him as a "celebrated techie."
Mandelson's usefulness to Palantir ended abruptly. He was removed from his ambassadorial post following disclosures of his association with Jeffrey Epstein. In 2026, allegations emerged that Mandelson had disclosed confidential government material to the convicted sex offender in 2009 and had counselled that his own administration face threats over proposed levies on bankers' bonuses.
The central question now concerns whether Watson possesses the political connections and influence needed to replace Mandelson's role as a well-positioned former Labour minister advocating for the firm.
A Pattern of Political Leverage
Palantir's accumulation of UK Government contracts demonstrates the substantial influence of political relationships and lobbying. Shortly after a confidential 2019 meeting between Palantir cofounder and board chair Peter Thiel and then-Prime Minister Boris Johnson—undisclosed at the time—the company secured its initial NHS contract, accepting just £1 in payment during the pandemic's peak.
From this initial foothold, Palantir expanded its presence through successive contracts, underpinned by continued political engagement and movement of personnel between the firm and government. Bloomberg reported that Mosley outlined the company's strategy in a September 2021 email titled "Buying our way in…!" which described "hoovering up" small businesses serving the NHS to "take a lot of ground and take down a lot of political resistance."
The circulation of staff between Palantir and government positions has become difficult to track comprehensively. NHS trust directors and chairs have been revealed as paid Palantir advisors; a senior civil servant at the Department of Health and Social Care advised a member of the Palantir-led NHS consortium; and former defence officials and senior ministers have been recruited by the firm.
One MP recently remarked of a departing senior civil servant overseeing the Federated Data Platform: "Given Palantir's habit of lobbying civil servants and the revolving door from government, I wait to see where she will end up."
Watson's recruitment thus exemplifies an established pattern rather than an anomaly. Yet this normalisation should not diminish concern. Palantir's substantial financial resources enable it to maintain an extensive network of former officials, political operatives, and advocates. Even where UK lobbying regulations are technically observed, the cumulative effect corrodes democratic integrity and compromises the public's capacity to make reasoned decisions about whether Thiel's corporation—with its explicit commitment to American technological supremacy—should occupy such a prominent position within British state institutions.
One potential indication of Palantir's vulnerability: the company's evident desperation to recruit Watson as a replacement for the now-discredited Mandelson may signal that it can no longer assume its role in the UK health service is secure.
